Pharmacokinetic studies have long been a key element of most Phase I and Phase II clinical studies. Pharmacodynamic studies and molecular correlates are now considered important components of these studies. With the increasing emphasis on the development of non-cytotoxic agents directed at novel targets, """"""""correlative"""""""" studies will be essential for the interpretation of the results and, in fact, may become the primary endpoint of the clinical studies. Therefore, the primary aim of the Analytical Pharmacology Core Facility (APCF) is to provide support for chemotherapy trials incorporating pharmacokinetic, pharmacodynamic and other correlative laboratory studies. An additional aim is to encourage and facilitate all cancer research, including basic and translational research, by providing a range of analytical services, such as LC/MS/MS, GC/MS, HPLC, and flameless Atomic Absorption Spectrometry (AAS). More specifically, the APCF provides expertise and equipment for (a) sample preparation and storage, including tissue samples for correlative studies, (b) analysis of chemotherapeutic drugs and related compounds, and (c) analysis and interpretation of pharmacokinetic and pharmacodynamic data. In addition, the APCF personnel provide consultation regarding appropriate analytical methods for research projects, study design, pharmacokinetic sampling schedules, and protocol review, and they collaborate in the preparation of manuscripts. During the 12-month reporting period, the APCF shared resource was used by 15 Cancer Center members from 4 Research Programs and one non-aligned member. Peer-reviewed usage represented 89% of total usage. Annual budget for this core is $292,151, of which 64% is institutional funding, 15% is user fees, and 21% ($60,100) is requested from the CCSG.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope/Beckman Research Institute
United States
Zip Code
Gu, Ying; Zhang, Jiawei; Ma, Xiaoxiao et al. (2017) Stabilization of the c-Myc Protein by CAMKII? Promotes T Cell Lymphoma. Cancer Cell 32:115-128.e7
Cao, Pengpeng; Mooney, Rachael; Tirughana, Revathiswari et al. (2017) Intraperitoneal Administration of Neural Stem Cell-Nanoparticle Conjugates Targets Chemotherapy to Ovarian Tumors. Bioconjug Chem 28:1767-1776
Mohanty, Suchismita; Mohanty, Atish; Sandoval, Natalie et al. (2017) Cyclin D1 depletion induces DNA damage in mantle cell lymphoma lines. Leuk Lymphoma 58:676-688
Wittenberg, Elaine; Ferrell, Betty; Koczywas, Marianna et al. (2017) Pilot Study of a Communication Coaching Telephone Intervention for Lung Cancer Caregivers. Cancer Nurs :
Yuan, Yuan; Vora, Nilesh; Sun, Can-Lan et al. (2017) Association of Pre-Chemotherapy Peripheral Blood Pro-Inflammatory and Coagulation Factors with Physical Function in Women with Breast Cancer. Oncologist 22:1189-1196
Deng, Ruishu; Hurtz, Christian; Song, Qingxiao et al. (2017) Extrafollicular CD4+ T-B interactions are sufficient for inducing autoimmune-like chronic graft-versus-host disease. Nat Commun 8:978
He, Zhiheng; Ma, Jian; Wang, Ruiqing et al. (2017) A two-amino-acid substitution in the transcription factor ROR?t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol 18:1128-1138
Kortylewski, Marcin; Moreira, Dayson (2017) Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities. Cancer Immunol Immunother 66:979-988
Somlo, George; Frankel, Paul H; Arun, Banu K et al. (2017) Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res 23:4066-4076
Slavin, Thomas P; Neuhausen, Susan L; Nehoray, Bita et al. (2017) The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes. Fam Cancer :

Showing the most recent 10 out of 1277 publications